Literature DB >> 27756096

Protective Effect of Irbesartan an Angiotensin (AT1) Receptor Antagonist in Unpredictable Chronic Mild Stress Induced Depression in Mice.

M Ayyub1, A K Najmi1, M Akhtar1.   

Abstract

Objective: Oxidative stress and alternation of renin-angiotensin system has been implicated in the pathophysiology of various cardio vascular, endocrine including mood and anxiety disorders. The present study evaluated the role of irbesartan in stress induced different models of depression. Materials and method: Mice were treated with irbesartan (40 mg/kg), fluoxetine (25 mg/kg) alone in combination orally. Drugs treatment started after 2 weeks from the beginning of the unpredictable mild stress (UCMS) protocol. Behavioural tests were performed on week 6, at least 24 h after the last treatment. Modified forced swim test (MFST), tail suspension test (TST) and open field test (OFT) were used followed by antioxidant markers and 5-HT levels determination. Result: Irbesartan increased swimming, climbing and decreased immobility times in MFST, decrease immobility time in TST. Irbesartan also increased no. of field crossings; rearings and also increased time spent in the centre of OFT. Thus, antidepressant like activity in UCMS mice was observed. Combination of irbesartan with fluoxetine showed potentiating effect of behavioural parameters in all animal models. Combination groups also showed antioxidant effects and elevated the 5-HT levels in UCMS mice.
Conclusion: Chronic administration of Irbesartan exerted antidepressant like effect, reduced oxidative stress and elevated brain 5-HT levels. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27756096     DOI: 10.1055/s-0042-118172

Source DB:  PubMed          Journal:  Drug Res (Stuttg)        ISSN: 2194-9379


  7 in total

Review 1.  The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.

Authors:  Natasha Ivanova; Jana Tchekalarova
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

Review 2.  Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It.

Authors:  Aswar Urmila; Patil Rashmi; Ghag Nilam; Bodhankar Subhash
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-11-30       Impact factor: 1.636

Review 3.  Cardiovascular therapeutics: A new potential for anxiety treatment?

Authors:  Kristina Repova; Silvia Aziriova; Kristina Krajcirovicova; Fedor Simko
Journal:  Med Res Rev       Date:  2022-01-06       Impact factor: 12.388

4.  Angiotensinergic Neurotransmissions in the Medial Amygdala Nucleus Modulate Behavioral Changes in the Forced Swimming Test Evoked by Acute Restraint Stress in Rats.

Authors:  Camila Marchi-Coelho; Willian Costa-Ferreira; Lilian L Reis-Silva; Carlos C Crestani
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

Review 5.  The renin-angiotensin system: a possible new target for depression.

Authors:  João Vian; Círia Pereira; Victor Chavarria; Cristiano Köhler; Brendon Stubbs; João Quevedo; Sung-Wan Kim; André F Carvalho; Michael Berk; Brisa S Fernandes
Journal:  BMC Med       Date:  2017-08-01       Impact factor: 8.775

Review 6.  Depression as an Immunometabolic Disorder: Exploring Shared Pharmacotherapeutics with Cardiovascular Disease.

Authors:  Mervin Chávez-Castillo; Manuel Nava; Ángel Ortega; Milagros Rojas; Victoria Núñez; Juan Salazar; Valmore Bermúdez; Joselyn Rojas-Quintero
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

7.  Hypertension Treatment Modality and Suicide Risk Among Veterans in Veterans Health Administration Care From 2015 to 2017.

Authors:  Kallisse R Dent; Cameron A Griffin; John F McCarthy; Ira R Katz
Journal:  JAMA Netw Open       Date:  2020-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.